Insights into parasites and COVID-19 co-infections in Iran: a systematic review.

IF 1.9 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Transactions of The Royal Society of Tropical Medicine and Hygiene Pub Date : 2024-06-04 DOI:10.1093/trstmh/trae001

Soheila Molaei, Shabnam Asfaram, Zahra Mashhadi, Behnam Mohammadi-Ghalehbin, Sohrab Iranpour

{"title":"Insights into parasites and COVID-19 co-infections in Iran: a systematic review.","authors":"Soheila Molaei, Shabnam Asfaram, Zahra Mashhadi, Behnam Mohammadi-Ghalehbin, Sohrab Iranpour","doi":"10.1093/trstmh/trae001","DOIUrl":null,"url":null,"abstract":"Background: It is well-documented that using immunosuppressive drugs such as corticosteroids or cytokine blockers in treating coronavirus disease 2019 (COVID-19) increases the risk of co-infections. Here we systematically summarized the cases of COVID-19-associated parasitic infections (CAPIs) in Iran.Methods: From 19 February 2020 to 10 May 2023, all studies on Iranian patients suffering from CAPIs were collected from several databases using a systematic search strategy.Results: Of 540 records, 11 studies remained for data extraction. In this research, most of the studies were related to Lophomonas and Toxoplasma. Of 411 cases of CAPIs, toxoplasmosis (385 [93.7%]) had the highest rate of infection among Iranian patients, followed by blastocystosis (15 [3.6%]), fascioliasis (4 [0.97%]), leishmaniasis (3 [0.7%]), lophomoniasis (3 [0.7%]) and strongyloidiasis (1 [0.2%]). In general, Blastocystis enhanced diarrhoea in patients with COVID-19. Lophomonas, Toxoplasma and Strongyloides increased the severity of COVID-19, but Fasciola decreased its intensity. Patients with a history of cutaneous leishmaniasis showed mild symptoms of COVID-19. Also, patients with a prior history of hydatid cysts were not affected by COVID-19.Conclusions: Due to the similar symptoms of some parasitic diseases and COVID-19 and immunosuppressive treatment regimens in these patients that may cause the reactivation or recurrence of parasitic infections, early diagnosis and treatment are required.","PeriodicalId":23218,"journal":{"name":"Transactions of The Royal Society of Tropical Medicine and Hygiene","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transactions of The Royal Society of Tropical Medicine and Hygiene","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/trstmh/trae001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background: It is well-documented that using immunosuppressive drugs such as corticosteroids or cytokine blockers in treating coronavirus disease 2019 (COVID-19) increases the risk of co-infections. Here we systematically summarized the cases of COVID-19-associated parasitic infections (CAPIs) in Iran.

Methods: From 19 February 2020 to 10 May 2023, all studies on Iranian patients suffering from CAPIs were collected from several databases using a systematic search strategy.

Results: Of 540 records, 11 studies remained for data extraction. In this research, most of the studies were related to Lophomonas and Toxoplasma. Of 411 cases of CAPIs, toxoplasmosis (385 [93.7%]) had the highest rate of infection among Iranian patients, followed by blastocystosis (15 [3.6%]), fascioliasis (4 [0.97%]), leishmaniasis (3 [0.7%]), lophomoniasis (3 [0.7%]) and strongyloidiasis (1 [0.2%]). In general, Blastocystis enhanced diarrhoea in patients with COVID-19. Lophomonas, Toxoplasma and Strongyloides increased the severity of COVID-19, but Fasciola decreased its intensity. Patients with a history of cutaneous leishmaniasis showed mild symptoms of COVID-19. Also, patients with a prior history of hydatid cysts were not affected by COVID-19.

Conclusions: Due to the similar symptoms of some parasitic diseases and COVID-19 and immunosuppressive treatment regimens in these patients that may cause the reactivation or recurrence of parasitic infections, early diagnosis and treatment are required.

查看原文本刊更多论文

对伊朗寄生虫和 COVID-19 合并感染的了解：系统综述。

背景：有充分证据表明，在治疗2019年冠状病毒病（COVID-19）时使用皮质类固醇激素或细胞因子阻断剂等免疫抑制剂会增加合并感染的风险。在此，我们系统地总结了伊朗与COVID-19相关的寄生虫感染（CAPIs）病例：从 2020 年 2 月 19 日至 2023 年 5 月 10 日，我们采用系统检索策略从多个数据库中收集了有关伊朗 CAPI 患者的所有研究：结果：在 540 条记录中，有 11 项研究仍在进行数据提取。在这项研究中，大多数研究与嗜血单胞菌和弓形虫有关。在 411 例 CAPI 中，弓形虫病（385 例 [93.7%]）在伊朗患者中的感染率最高，其次是囊虫病（15 例 [3.6%]）、筋膜炎（4 例 [0.97%]）、利什曼病（3 例 [0.7%]）、嗜线虫病（3 例 [0.7%]）和强线虫病（1 例 [0.2%]）。一般来说，COVID-19 患者的腹泻症状会因布氏杆菌而加重。嗜血单胞菌、弓形虫和强直性线虫病会增加 COVID-19 的严重程度，但法氏囊虫会降低其严重程度。有皮肤利什曼病病史的患者 COVID-19 的症状较轻。此外，有包虫囊肿病史的患者也不会受到 COVID-19 的影响：结论：由于某些寄生虫病的症状与 COVID-19 相似，而且这些患者的免疫抑制治疗方案可能会导致寄生虫感染的再激活或复发，因此需要及早诊断和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transactions of The Royal Society of Tropical Medicine and Hygiene 医学-公共卫生、环境卫生与职业卫生

CiteScore

4.00

自引率

9.10%

发文量

115

审稿时长

4-8 weeks

期刊介绍： Transactions of the Royal Society of Tropical Medicine and Hygiene publishes authoritative and impactful original, peer-reviewed articles and reviews on all aspects of tropical medicine.